Sponsor

Ascenta Therapeutics

Clinical research sponsor

Published trials7

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

7 shown

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)NCT00571675 · lead sponsor · 2007-10-01

COMPLETED

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung CancerNCT00544960 · lead sponsor · 2007-09-01

COMPLETED

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung CancerNCT00397293 · lead sponsor · 2006-11-01

COMPLETED

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPCNCT00286793 · lead sponsor · 2006-02-01

COMPLETED

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate CancerNCT00286806 · lead sponsor · 2005-12-01

COMPLETED

Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung CancerNCT00934076 · collaborator · 2010-02-01

WITHDRAWN

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsNCT00988169 · collaborator · 2009-09-01

TERMINATED

Sponsor roles

lead sponsor5

collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.